- Home
- CAPR vs MSB Comparison
CAPR vs MSB Comparison
Compare CAPR & MSB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CAPR
- MSB
- Stock Information
- Founded
- CAPR 2005
- MSB 1961
- Country
- CAPR United States
- MSB United States
- Employees
- CAPR N/A
- MSB N/A
- Industry
- CAPR Biotechnology: Biological Products (No Diagnostic Substances)
- MSB Metal Mining
- Sector
- CAPR Health Care
- MSB Basic Materials
- Exchange
- CAPR Nasdaq
- MSB Nasdaq
- Market Cap
- CAPR 324.6M
- MSB 320.9M
- IPO Year
- CAPR N/A
- MSB N/A
- Fundamental
- Price
- CAPR $6.28
- MSB $30.92
- Analyst Decision
- CAPR Strong Buy
- MSB
- Analyst Count
- CAPR 8
- MSB 0
- Target Price
- CAPR $24.75
- MSB N/A
- AVG Volume (30 Days)
- CAPR 1.4M
- MSB 48.2K
- Earning Date
- CAPR 08-11-2025
- MSB 01-01-0001
- Dividend Yield
- CAPR N/A
- MSB 22.43%
- EPS Growth
- CAPR N/A
- MSB 335.65
- EPS
- CAPR N/A
- MSB 7.12
- Revenue
- CAPR $13,392,150.00
- MSB $25,894,592.00
- Revenue This Year
- CAPR N/A
- MSB N/A
- Revenue Next Year
- CAPR $6,061.53
- MSB N/A
- P/E Ratio
- CAPR N/A
- MSB $4.34
- Revenue Growth
- CAPR N/A
- MSB N/A
- 52 Week Low
- CAPR $3.98
- MSB $16.55
- 52 Week High
- CAPR $23.40
- MSB $37.00
- Technical
- Relative Strength Index (RSI)
- CAPR 36.33
- MSB 54.91
- Support Level
- CAPR $6.17
- MSB $30.68
- Resistance Level
- CAPR $7.30
- MSB $33.25
- Average True Range (ATR)
- CAPR 0.43
- MSB 1.06
- MACD
- CAPR -0.11
- MSB -0.24
- Stochastic Oscillator
- CAPR 4.53
- MSB 27.41
About CAPR Capricor Therapeutics Inc.
Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat.
About MSB Mesabi Trust
Mesabi Trust operates as a royalty trust in the United States. The company is involved in the conservation and protection of its assets. The company's principally wholly-owned segment is the iron ore mining segment, which generates income from the Peter Mitchell Mine, an iron mine located near Babbitt, Minnesota, at the eastern end of the Mesabi Iron Range.